PFE
Pfizer Inc
Q3 2024 Report
Pfizer Inc (PFE) Q3 2024 Financial Results: Strong Performance Amidst Strategic Growth Plans...
Read full report
Executive Summary
Pfizer Inc reported an impressive Q4 2024, achieving $17.8 billion in revenues, representing a 21.9% increase from the previous year. Revenue from non-COVID products rose by 11% year-over-year, with significant contributions from key medications including Vyndaqel, Padcev, and Eliquis. Management expressed optimism regarding a revamped research and development (R&D) approach and the integration of Seagen, intended to enhance market position within oncology. Despite gross margin pressures from COVID-related products and the impact of Medicare pricing reforms, the company maintains a solid profit outlook, reinforced by disciplined capital allocation strategies and ongoing cost reduction efforts.
Key Performance Indicators
Revenue
17.76B
QoQ: 0.34% | YoY:19.38%
Gross Profit
11.85B
66.73% margin
QoQ: 6.53% | YoY:12.92%
Operating Income
3.19B
QoQ: -39.69% | YoY:-30.09%
Net Income
410.00M
QoQ: -90.82% | YoY:-86.84%
EPS
0.07
QoQ: -90.85% | YoY:-86.85%
Revenue Trend
Margin Analysis
Key Insights
**Revenue:** $17.8 billion (+21.9% YoY, +0.34% QoQ) **Gross Profit:** $11.85 billion (Gross Profit Margin: 66.7%) **Operating Income:** $3.19 billion (Operating Margin: 17.9%) **Net Income:** $410 million (Net Margin: 2.3%) **EPS (Diluted):** $0.0719 **Cash Flow from Operations:** $6.55 billion **Debt Ratio:** 29.8% **Long-Term Debt to Capitalization:** 39.1% Management noted capital allocation priorities focusing on strengthening R&D investments, targeting a gross leverage of 3.25x b...